drugset / Trial / NCT06472076
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.
Timeline
- Start
- 2024-06-10
- Primary completion
- 2026-06-30
- Completion
- 2027-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belrestotug | Monoclonal antibody | — | — |
| Subject | Dostarlimab | Monoclonal antibody | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |